Objective To investigate the clinical value and therapeutic effect of biliary stent insertion(EMBE, ERBD)and ENBD via endoscopic retrograde cholangio-pancreatography(ERCP)on malignant obstructive jaundice.Methods A retrospective review was conducted of 51 patients with malignant obstructive jaundice receiving ERCP in our hospital from June 2002 to March 2009.Different biliary stents or ENBD were placed into their biliary duct to drain bile.Meanwhile, the efective power, incidence rate, unobstructive time, and live time were determined.Results ERCP was successfully performed in all these 51 cases and 31 of them were successfully embedded with self-expandable metal stents while 15 of them had plastic stents.The last 2 cases were only treated with ENBD.Eleven cases had complications, but none of them had sequela after prompt treatment.In 48 cases, the serum level of total bilirubin decreased from(279.6±143.7)μmol/L to(125.7±78.3)μmol/L after drainage(P＜0.01).The follow-up investigation in 39 cases indicated that the 3-and 6-month survival rates after the treatment were 91% and 74%, respectively.Conclusion Biliary stent insertion and ENBD via duodenoscopy is an effective and safe palliative treatment for malignant bile duct obstruction.

Objective:To explore the prognostic value of ferroptosis-related long non-coding RNA (lncRNA) in esophageal cancer.Methods:Based on the Cancer Genome Atlas (TCGA), the predictive model was constructed based on the differentially expressed ferroptosis-related lncRNAs in esophageal cancer.Results:Seventeen differentially expressed ferroptosis-related lncRNAs (AC108673.2, LINC00942, CASC8, AP003696.1, LINC02154, AC092969.1, AC245100.5, AC011379.1, TMEM161B-AS1, LINC00092, LINC01977, AC107308.1, LINC00261, LINC00592, AP000553.2, HOXC-AS1, Z93403.1) related to the prognosis of esophageal cancer were identified. Kaplan-Meier analysis showed that the high-risk lncRNA feature was associated with a poor prognosis of esophageal cancer ( P<0.01). The area under the curve of the lncRNA feature was 0.861 at 1-year, 0.828 at 2-year, 0.764 at 3-year; and it showed superiority over conventional clinical pathology features in predicting the prognosis of esophageal cancer. In addition, there were significant differences in immune cells between the low-risk and high-risk groups. The immune checkpoints such as TNFSF 9, CD70 and TNFRSF 25 were also different expression between the two risk groups. Conclusions:Ferroptosis-related lncRNA signature can precisely predict the prognosis of esophageal cancer and serve as therapeutic targets for esophageal cancer.